Overview

Rifamycin in Minimal Hepatic Encephalopathy

Status:
Recruiting
Trial end date:
2022-11-15
Target enrollment:
Participant gender:
Summary
This is a randomized double-blind placebo-controlled trial of MHE in patients with cirrhosis using rifamycin SV-MMX 600mg BID vs placebo for 30 days with PK, safety, microbiota, brain function and brain MRI endpoints.
Phase:
Phase 2
Details
Lead Sponsor:
Hunter Holmes Mcguire Veteran Affairs Medical Center
Treatments:
Rifamycin SV
Rifamycins